Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer
Phase 3
Completed
- Conditions
- Advanced Non-small Cell Lung Cancer
- Interventions
- Drug: Placebos
- First Posted Date
- 2017-04-17
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Jiangsu Wuzhong Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 560
- Registration Number
- NCT03117335
- Locations
- 🇨🇳
Bengbu medical college affiliated hospital, Bengbu, Anhui, China
🇨🇳Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China
🇨🇳The first affiliated hospital, anhui medical university, Hefei, Anhui, China
© Copyright 2025. All Rights Reserved by MedPath